[go: up one dir, main page]

MXPA04005221A - Lactamas como antagonistas de taquiquininas. - Google Patents

Lactamas como antagonistas de taquiquininas.

Info

Publication number
MXPA04005221A
MXPA04005221A MXPA04005221A MXPA04005221A MXPA04005221A MX PA04005221 A MXPA04005221 A MX PA04005221A MX PA04005221 A MXPA04005221 A MX PA04005221A MX PA04005221 A MXPA04005221 A MX PA04005221A MX PA04005221 A MXPA04005221 A MX PA04005221A
Authority
MX
Mexico
Prior art keywords
optionally
ring
heterocycle
optionally substituted
hetb
Prior art date
Application number
MXPA04005221A
Other languages
English (en)
Inventor
Stuar Middleton Donald
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA04005221A publication Critical patent/MXPA04005221A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de formula (I):(ver formula)o una sal, profarmaco, solvato o polimorfo farmaceuticamente aceptable del mismo, en la que R es het??; R1 es fenilo opcionalmente sustituido con uno o mas sustituyentes; m es 1-4, Z se selecciona de: a) N(R3) (R4X)a. en la que X es NR3R5, OR3, O-arilo1, O-hetb, O-hetc, arilo1, hetb o hetc;b) N(R3)Y en la que Y es arilo1, hetb, o hetc; yc) un heterociclo saturado o parcialmente saturado que contiene N de 4 a 7 miembros unido al enlace alquileno a traves del citado atomo de nitrogeno, conteniendo opcionalmente el citado heterociclo 1-3 grupos adicionales, seleccionado cada uno independientemente de C=O, NH, S(O)p y O; opcionalmente el citado heterociclo esta:a) espirocondensado con hetb, de tal modo que ambos anillos comparten un atomo; ob) opcionalmente sustituido independientemente con 1-3 grupos;en la que R3 y R6 se seleccionan ambos independientemente de H y alquilo C1-6;en la que R4 se selecciona de alquileno C1-6; en la que R5 se selecciona de C(O)OR3, S(O)pR3, S(O)parilo1, C(O)R3 Y C(O)NR3R6; hetb es un heterociclo de 4-7 miembros que contiene 1.3 heteroatomos, seleccionado cada uno independientemente de N, O y S, estando el citado N opcionalmente sustituido con O, conteniendo opcionalmente el citado anillo 1-2 grupos C=O, estando el citado anillo saturado o parcialmente saturado, estando el citado anillo benzocondensado, estando el citado anillo opcionalmente sustituido con 1-3 sustituyentes; heta y hetc son un heterociclo aromatico de 5-7 miembros que contiene 1-3 heteroatomos seleccionado cada uno independientemente de N, O y S, estando el citado anillo opcionalmente benzocondensado, estando el citado sistema de anillo en conjunto opcionalmente sustituido con 1-3 sustituyentes; arilo1 es fenilo o naftilo, estando cada uno opcionalmente sustituido con 1-3 sustituyentes, p es 0, 1 o 2; y n es 0-4; son utiles en el tratamiento o la prevencion de una afeccion para la que es eficaz un antagonista de NK2.
MXPA04005221A 2001-12-18 2002-12-06 Lactamas como antagonistas de taquiquininas. MXPA04005221A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0130261.1A GB0130261D0 (en) 2001-12-18 2001-12-18 Lactams as tachykinin antagonists
PCT/IB2002/005234 WO2003051868A1 (en) 2001-12-18 2002-12-06 Lactams as tachykinin antagonists

Publications (1)

Publication Number Publication Date
MXPA04005221A true MXPA04005221A (es) 2004-08-19

Family

ID=9927858

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005221A MXPA04005221A (es) 2001-12-18 2002-12-06 Lactamas como antagonistas de taquiquininas.

Country Status (16)

Country Link
US (1) US7060836B2 (es)
EP (1) EP1456200A1 (es)
JP (1) JP2005514389A (es)
AR (1) AR037852A1 (es)
AU (1) AU2002366320A1 (es)
BR (1) BR0215017A (es)
CA (1) CA2470236A1 (es)
GB (1) GB0130261D0 (es)
GT (1) GT200200280A (es)
HN (1) HN2002000365A (es)
MX (1) MXPA04005221A (es)
PA (1) PA8561501A1 (es)
PE (1) PE20030718A1 (es)
TW (1) TW200302097A (es)
UY (1) UY27588A1 (es)
WO (1) WO2003051868A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199250B2 (en) 2002-12-20 2007-04-03 Battelle Memorial Institute Process for producing cyclic compounds
FR2873373B1 (fr) * 2004-07-23 2006-09-08 Sanofi Synthelabo Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
JP2008521821A (ja) * 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
US7786308B2 (en) * 2005-03-28 2010-08-31 Vertex Pharmaceuticals Incorporated Muscarinic modulators
JP2009507800A (ja) 2005-09-09 2009-02-26 ユーロ−セルティーク エス．エイ． 縮合およびスピロ環化合物ならびにその使用
WO2007086559A1 (ja) * 2006-01-27 2007-08-02 Ube Industries, Ltd. テトラヒドロピラン化合物の製造方法
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
EP2021005A4 (en) * 2006-05-03 2009-11-25 Cnsbio Pty Ltd METHOD AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY PAIN
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US7592345B2 (en) * 2007-06-13 2009-09-22 Hoffmann-La Roche Inc. Piperazine and [1,4]diazepan derivatives as NK antagonists
EP2175886A1 (en) * 2007-06-28 2010-04-21 CNSBio Pty Ltd Combination methods and compositions for treatment of neuropathic pain
ES2382415T3 (es) * 2007-09-14 2012-06-08 F. Hoffmann-La Roche Ag Derivados de piperidina como antagonistas de receptores de NK3
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
RS56111B1 (sr) * 2011-03-23 2017-10-31 Trevena Inc Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme
AU2016372028B2 (en) 2015-12-14 2022-02-17 Trevena, Inc. Methods of treating hyperalgesia
WO2017126635A1 (ja) * 2016-01-22 2017-07-27 武田薬品工業株式会社 複素環化合物およびその用途
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN112321599B (zh) * 2020-11-25 2023-05-30 合肥远志医药科技开发有限公司 一种药物中间体7-氧代-2-氮杂螺[3.5]壬烷的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
GB9600235D0 (en) * 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
AU2002366320A1 (en) 2003-06-30
CA2470236A1 (en) 2003-06-26
PA8561501A1 (es) 2003-07-28
UY27588A1 (es) 2003-07-31
GB0130261D0 (en) 2002-02-06
JP2005514389A (ja) 2005-05-19
US7060836B2 (en) 2006-06-13
TW200302097A (en) 2003-08-01
WO2003051868A1 (en) 2003-06-26
AR037852A1 (es) 2004-12-09
GT200200280A (es) 2003-07-11
EP1456200A1 (en) 2004-09-15
US20040132710A1 (en) 2004-07-08
PE20030718A1 (es) 2003-08-18
HN2002000365A (es) 2003-07-23
BR0215017A (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
MXPA04005221A (es) Lactamas como antagonistas de taquiquininas.
DK0683789T3 (da) N-alkyl-2-substituerede ATP-analoger
HUP0402679A2 (hu) Pirrolidin- és piperidin-származékok mint NK1 antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
MXPA05009205A (es) Derivados de dihidroxiisoxasol hidroximetil sustituidos utiles como agentes antibioticos.
HUP0303183A2 (hu) Gerinctelen kártevőírtó hatású heterociklusos diamidszármazékok, azokat tartalmazó készítmények és alkalmazásuk
DE60330910D1 (de) Verbindungen mit selektiverinhibierender wirkung für gsk3
TW200716528A (en) Cyclopropanecarboxamide derivatives
NO981609D0 (no) Fusjonerte tropanderivater som inhiberer for neurotransmitteropptak
JO2413B1 (en) Benzoxazine derivatives and their use
MY136824A (en) Substituted benzoxazinones and uses thereof
WO2003008412A3 (en) Hetero-bicyclic crf antagonists
MY118004A (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
HRP20050775A2 (en) Quinolinone/benzoxazinone derivatives and uses thereof
DE69933885D1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
BG106814A (en) Quaternary salts of n-substituted cyclic or acyclic amines as pharmaceuticals
MY125037A (en) 1,2,3,4 tetrahydroquinoline derivatives
MXPA04000036A (es) Benzofuranos sustituidos con (hetero) arilo como ligandos 5-ht.
DE60226971D1 (de) Corticotropinfreisetzungsfaktor antagonisten
BR9711948A (pt) Composto processo para produzir um composto composi-Æo farmac-utica e uso de um composto
TH16326A (th) อาริลอัลคิลอะมีนต่าง ๆ ขบวนการในการเตรียมสารเหล่านี้ และส่วนผสมทางเภสัชกรรมที่มีสารเหล่านี้
MX9603735A (es) Compuestos fungicidas.
CA2236851A1 (en) Substituted vinylpyridine derivatives and drugs containing the same
TH78128A (th) สารประกอบชนิดใหม่

Legal Events

Date Code Title Description
FA Abandonment or withdrawal